KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Debt (2018 - 2025)

Historic Total Debt for Castle Biosciences (CSTL) over the last 6 years, with Q3 2025 value amounting to $10.0 million.

  • Castle Biosciences' Total Debt rose 33.95% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 33.95%. This contributed to the annual value of $10.0 million for FY2024, which is N/A changed from last year.
  • Per Castle Biosciences' latest filing, its Total Debt stood at $10.0 million for Q3 2025, which was up 33.95% from $10.0 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Total Debt peaked at $20.8 million during Q1 2022, and registered a low of $10.0 million during Q1 2024.
  • In the last 3 years, Castle Biosciences' Total Debt had a median value of $10.0 million in 2024 and averaged $11.4 million.
  • Examining YoY changes over the last 5 years, Castle Biosciences' Total Debt showed a top increase of 33.95% in 2025 and a maximum decrease of 31.97% in 2025.
  • Castle Biosciences' Total Debt (Quarter) stood at $20.8 million in 2022, then plummeted by 51.93% to $10.0 million in 2024, then increased by 0.26% to $10.0 million in 2025.
  • Its last three reported values are $10.0 million in Q3 2025, $10.0 million for Q2 2025, and $10.0 million during Q1 2025.